Avalon GloboCare Corp. (AVCO) News

Avalon GloboCare Corp. (AVCO): $0.70

0.14 (+25.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter AVCO News Items

AVCO News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest AVCO News From Around the Web

Below are the latest news stories about AVALON GLOBOCARE CORP that investors may wish to consider to help them evaluate AVCO as an investment opportunity.

Avalon GloboCare Announces Publication Featuring QTY Code Technology in the Official Journal of the American Chemical Society

Findings support utility of QTY protein code as a novel platform to generate water-soluble proteins for wide spectrum of biomedical applications Reports plans to apply for additional patents related to QTY code applications jointly with MIT FREEHOLD, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new publication featuring the Company’s QTY protein code technology i

Yahoo | August 8, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Good morning!

William White on InvestorPlace | July 28, 2022

Avalon GloboCare Announces New Study Featuring AI-Enhanced Protein Design Technology Targeting Glucose Transporter Against Cancer

FREEHOLD, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, today announced a new study applying artificial intelligence (AI) enhanced protein design “QTY Code” technology. The method is expected to accelerate development of therapeutic monoclonal antibodies to treat cancer. The research demonstrates a novel method for quickly predicting the design of so-called “water-loving” or hydrop

Yahoo | June 30, 2022

Even after rising 13% this past week, Avalon GloboCare (NASDAQ:AVCO) shareholders are still down 73% over the past three years

It's nice to see the Avalon GloboCare Corp. ( NASDAQ:AVCO ) share price up 13% in a week. But the last three years have...

Yahoo | June 1, 2022

Avalon GloboCare to Present at the Jefferies 2022 Healthcare Conference

FREEHOLD, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that David Jin, M.D., Ph.D., President and Chief Executive Officer, and Luisa Ingargiola, Chief Financial Officer, of Avalon GloboCare, will be presenting at the Jefferies 2022 Healthcare Conference which is being held on June 8–10, 2022 in New York City. Management is scheduled to present on Friday, June 10, 20

Yahoo | May 25, 2022

Avalon GloboCare Signs MOU to Form Strategic Partnership with Lu Daopei Hematology Institute to Develop Precision Companion Diagnostics for Cellular Therapy

Goal of Partnership is to expand Avalon’s R&D pipeline to include innovative companion diagnostics in association with the company’s ongoing and future cellular immunotherapy clinical programs Appoints Dr. Hongxing Liu, a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board to further strengthen Avalon’s companion diagnostics development capabilities FREEHOLD, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASD

Yahoo | May 18, 2022

10 Penny Stocks to Buy in May

In this article, we will look at 10 penny stocks to buy in May. If you want to explore similar stocks that have the potential to explode in the future, you can also take a look at 5 Penny Stocks to Buy in May. Predicting the future might be a little far-fetched, but that does […]

Yahoo | May 10, 2022

Avalon GloboCare Expands IP Portfolio; Files 16 New Patent Applications

Co-inventors are leading international universities and cellular therapy developers Patent applications cover three types of cellular therapies and related technologies FREEHOLD, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of innovative cell-based technologies and therapeutics, announced today that the Company has jointly filed 16 patent applications, co-invented with key strategic partners, including a top-5 U.S. university, a leadi

Yahoo | April 27, 2022

Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform

Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors. The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T c

Yahoo | February 14, 2022

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies

Leveraging Avalon’s existing Flash-CARTM technology platform to develop next-generation mRNA-based CAR-NK cellular therapeuticsClinical development of CAR-NK cell therapy planned in collaboration with the Company’s clinical partner, Lu Daopei Hospital, as a potential treatment for hematologic malignancies and other unmet medical areasAppoints Dongfang Liu, Ph.D., a world-class scientist and expert in CAR-NK technology, to Avalon’s Scientific and Clinical Advisory Board FREEHOLD, N.J., Feb. 14, 2

Yahoo | February 14, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5308 seconds.